Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Women with GERD can make do with lower PPI doses

20 Jun 2017

Female patients taking long-term proton pump inhibitors (PPIs) have threefold odds of tolerating half of their prior dose, suggesting that the female gender is associated with an increased probability for successful step-down, according to a recent study.

A double-blind randomized trial was conducted to determine the proportion of patients with gastro-oesophageal reflux disease (GERD) on PPI therapy who could reduce their prior dosage by half and to identify predictors of successful step-down.

Researchers randomly assigned a total of 100 patients with endoscopically verified erosive oesophagitis on long-term PPI therapy to either step down their dose by half (n=51; 25 females) or continue with the same dose for 8 weeks (n=49; 24 females). Fasting gastrin levels were measured before and after treatment. Successful step-down throughout the study period was the primary endpoint.

Female patients, compared with male patients, had higher gastrin levels (78 vs 50 pg/mL; p=0.007). Among the participants assigned to the step-down intervention, only 3/25 (12 percent) women did not complete the 2 months of lower-dose therapy vs 9/25 (36 percent) men (p=0.09).

The strongest predictor for successful step-down was female gender (odds ratio, 1.27; 95 percent CI, 1.01 to 1.60). The reduction group had a twofold chance of failure in maintaining symptom control as compared with the control group (24 vs 13 percent; p=0.2).

“These results indicate that women with gastro-oesophageal reflux disease might manage with lower doses of PPIs as compared with men,” researchers said.

Gastric acid inhibition leads to appropriate hypergastrinemia, and a gender difference has been shown in fasting gastrin, with greater levels observed among women than men on long-term PPI therapy, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.